Tarsus Pharmaceuticals is a biotech company focused on developing treatments for eye conditions, with its lead drug candidate targeting a specific type of eyelid inflammation caused by microscopic mites.
The company generates revenue from selling its lead product, with annual revenue reaching USD 0.45B in 2025. Despite high gross margins above 90%, the company is not yet profitable, posting a net loss of USD 0.07B in 2025.
Tarsus's moat is eroding. While its lead product has strong patent protection and a novel mechanism, the company faces potential competition from established ophthalmology players like AbbVie and Novartis, who have larger sales forces and deeper pockets to com
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
